Status:
UNKNOWN
18F-FAPI-RGD PET/CT in Various Tumor Types
Lead Sponsor:
Sichuan Provincial People's Hospital
Conditions:
Neoplasms
Eligibility:
All Genders
10-80 years
Brief Summary
The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with various types of tumor, and the results will be compared with those of 18F-FDG.
Detailed Description
The aim of this study is to evaluate, in patients with various types of tumor, the radiotracer uptake and clinical feasibility of 18F-FAPI-RGD PET/CT compared with those of 18F-FDG PET/CT. To evaluate...
Eligibility Criteria
Inclusion
- Patients with clinically suspected or diagnosed tumors
Exclusion
- Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg
- Complicated with chronic liver disease, myocardial infarction, stroke
- Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception
- Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
Key Trial Info
Start Date :
April 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06094530
Start Date
April 10 2023
End Date
October 1 2024
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072